PellePharm Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

PellePharm is a San Francisco-based biotechnology company focused on developing treatments for rare dermatologic diseases. It targets the hedgehog signaling pathway at the disease source, employing a topical gel to address Gorlin syndrome and high-frequency basal cell carcinomas, with the aim of reducing the need for repetitive surgeries in a field where surgery is the standard of care. The burden of these conditions can include numerous procedures, underscoring the potential value of non-surgical options.

Its lead therapy, patidegib gel, is designed to minimize systemic exposure and the related side effects seen with oral treatments. PellePharm has pursued partnerships such as a strategic alliance with Leo Pharma and has earned regulatory designations recognizing the potential of patidegib topical gel for Gorlin syndrome, including FDA Orphan Drug and Breakthrough Therapy designations. The drug is in Phase III evaluation for Basal cell nevus syndrome, and the company is characterized as a small-to-mid-sized enterprise within the biotechnology research sector.

Sign up for free to view info

Company overview Employee directory